J Korean Med Sci.  2024 Feb;39(6):e51. 10.3346/jkms.2024.39.e51.

Increased Apolipoprotein B/ Apolipoprotein A-I Ratio Is Associated With Decline in Lung Function in Healthy Individuals: The Kangbuk Samsung Health Study

• Lee J
• Park HK
• Kwon MJ
• Ham SY
• Gil HI
• Lim SY
• Song JU

• KMID: 2553303
• DOI: http://doi.org/10.3346/jkms.2024.39.e51

Abstract

Background
Lung dysfunction and high apolipoprotein B/apolipoprotein A-I (apoB/apoA-I) ratio are both recognized risk factors for cardiovascular disease. However, few studies have examined the association between the apoB/ApoA-I ratio and lung function. Therefore, we investigated whether this ratio is associated with decreased lung function in a large healthy cohort.
Methods
We performed a cohort study on 68,418 healthy Koreans (34,797 males, mean age: 38.1 years) who underwent a health examination in 2019. ApoB/apoA-I ratio was categorized into quartiles. Spirometric values at the fifth percentile in our population were considered the lower limit of normal (LLN), which was used to define lung function impairment. Adjusted odds ratios (aORs) and 95% confidence intervals (CIs), using the lowest quartile as the reference, were estimated to determine lung function impairment.
Results
Mean apoB/apoA-I ratio was 0.67 ± 0.21. Subjects with the highest quartile of this ratio had the lowest predicted forced expiratory volume in one second (FEV₁ %) and forced vital capacity (FVC%) after controlling for covariates (P < 0.001). However, FEV₁ /FVC ratio was not significantly different among the four quartiles (P = 0.059). Compared with the lowest quartile (Q1, reference), the aORs (95% CI) for FEV₁ % < LLN across increasing quartiles (from Q2 to Q4) were 1.216 (1.094–1.351), 1.293 (1.156–1.448), and 1.481 (1.311– 1.672) (P for trend < 0.001), respectively. Similarly, the aORs for FVC% < LLN compared with the reference were 1.212 (1.090–1.348), 1.283 (1.147–1.436), and 1.502 (1.331–1.695) with increasing quartiles (P for trend < 0.001). However, the aORs for FEV₁ /FVC < LLN were not significantly different among groups (P for trend = 0.273).
Conclusion
High apoB/apoA-I ratio was associated with decreased lung function. However, longitudinal follow-up studies are required to validate our findings.

Keyword

Apolipoprotein A-I; Apolipoprotein B; ApoB/A-I Ratio; Lung Function; Healthy Population; Spirometry

Figure

• 

  Fig. 1 Flow chart of study participants. Details of comorbidities were unavailable because the medical history questionnaire only required yes/no responses. As some individuals had more than one exclusion criterion, 73,795 participants were ultimately included in the analysis.COPD = chronic obstructive pulmonary disease, BA = bronchial asthma, HBsAg = hepatitis B virus surface antigen, HCV-Ab = hepatitis C virus antibody, MS = metabolic syndrome, HDL = high-density lipoprotein.

Reference

1. Leone N, Courbon D, Thomas F, Bean K, Jégo B, Leynaert B, et al. Lung function impairment and metabolic syndrome: the critical role of abdominal obesity. Am J Respir Crit Care Med. 2009; 179(6):509–516. PMID: 19136371.

2. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2005; 127(6):1952–1959. PMID: 15947307.

3. Engström G, Hedblad B, Nilsson P, Wollmer P, Berglund G, Janzon L. Lung function, insulin resistance and incidence of cardiovascular disease: a longitudinal cohort study. J Intern Med. 2003; 253(5):574–581. PMID: 12702035.

4. Lim SY, Rhee EJ, Sung KC. Metabolic syndrome, insulin resistance and systemic inflammation as risk factors for reduced lung function in Korean nonsmoking males. J Korean Med Sci. 2010; 25(10):1480–1486. PMID: 20890430.

5. Bae MS, Han JH, Kim JH, Kim YJ, Lee KJ, Kwon KY. The relationship between metabolic syndrome and pulmonary function. Korean J Fam Med. 2012; 33(2):70–78. PMID: 22745890.

6. Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax. 2003; 58(5):388–393. PMID: 12728157.

7. Çolak Y, Afzal S, Nordestgaard BG, Lange P, Vestbo J. Importance of early COPD in young adults for development of clinical COPD: findings from the Copenhagen General Population Study. Am J Respir Crit Care Med. 2021; 203(10):1245–1256. PMID: 33142077.

8. Davidson MH. Apolipoprotein measurements: is more widespread use clinically indicated? Clin Cardiol. 2009; 32(9):482–486. PMID: 19743499.

9. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999; 340(2):115–126. PMID: 9887164.

10. Shaaban R, Kony S, Driss F, Leynaert B, Soussan D, Pin I, et al. Change in C-reactive protein levels and FEV₁ decline: a longitudinal population-based study. Respir Med. 2006; 100(12):2112–2120. PMID: 16650972.

11. Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence. J Intern Med. 2006; 259(5):493–519. PMID: 16629855.

12. Jung CH, Hwang JY, Shin MS, Yu JH, Kim EH, Bae SJ, et al. Association of apolipoprotein b/apolipoprotein A1 ratio and coronary artery stenosis and plaques detected by multi-detector computed tomography in healthy population. J Korean Med Sci. 2013; 28(5):709–716. PMID: 23678262.

13. Lee J, Park HK, Kwon MJ, Ham SY, Gil HI, Lim SY, et al. The impact of insulin resistance on the association between metabolic syndrome and lung function: the Kangbuk Samsung Health Study. Diabetol Metab Syndr. 2023; 15(1):65. PMID: 37005609.

14. Kim BY, Kang SM, Kang JH, Kang SY, Kim KK, Kim KB, et al. 2020 Korean Society for the Study of Obesity guidelines for the management of obesity in Korea. J Obes Metab Syndr. 2021; 30(2):81–92. PMID: 34045368.

15. Jung CH, Lee WJ, Song KH. Metabolically healthy obesity: a friend or foe? Korean J Intern Med. 2017; 32(4):611–621. PMID: 28602062.

16. Chang Y, Kim BK, Yun KE, Cho J, Zhang Y, Rampal S, et al. Metabolically-healthy obesity and coronary artery calcification. J Am Coll Cardiol. 2014; 63(24):2679–2686. PMID: 24794119.

17. Hwang YC, Ahn HY, Kim WJ, Park CY, Park SW. Increased apoB/A-I ratio independently associated with type 2 diabetes mellitus: cross-sectional study in a Korean population. Diabet Med. 2012; 29(9):1165–1170. PMID: 22356423.

18. World Health Organization. The Asia-Pacific Perspective: Redefining Obesity and Its Treatment. Geneva, Switzerland: World Health Organization;2000.

19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7):412–419. PMID: 3899825.

20. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005; 26(2):319–338. PMID: 16055882.

21. Choi HS, Park YB, Yoon HK, Lim SY, Kim TH, Park JH, et al. Validation of previous spirometric reference equations and new equations. J Korean Med Sci. 2019; 34(47):e304. PMID: 31808325.

22. Hong Y, Ra SW, Shim TS, Lim CM, Koh Y, Lee SD, et al. Poor interpretation of pulmonary function tests in patients with concomitant decreases in FEV₁ and FVC. Respirology. 2008; 13(4):569–574. PMID: 18410263.

23. Stanojevic S, Kaminsky DA, Miller MR, Thompson B, Aliverti A, Barjaktarevic I, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J. 2022; 60(1):2101499. PMID: 34949706.

24. Gordon EM, Figueroa DM, Barochia AV, Yao X, Levine SJ. High-density lipoproteins and apolipoprotein A-I: potential new players in the prevention and treatment of lung disease. Front Pharmacol. 2016; 7:323. PMID: 27708582.

25. Gowdy KM, Fessler MB. Emerging roles for cholesterol and lipoproteins in lung disease. Pulm Pharmacol Ther. 2013; 26(4):430–437. PMID: 22706330.

26. Cirillo DJ, Agrawal Y, Cassano PA. Lipids and pulmonary function in the Third National Health and Nutrition Examination Survey. Am J Epidemiol. 2002; 155(9):842–848. PMID: 11978588.

27. Huerta-Ramírez S, Paniagua-Pérez A, Castro-Serna D, Ledesma-Velázquez A, Rubio-Guerra A, Vargas-Ayala G. Effect of the components of the metabolic syndrome on pulmonary function. The unexpected role of high-density lipoprotein cholesterol. Cir Cir. 2018; 86(2):175–181. PMID: 29809185.

28. Freyberg J, Landt EM, Afzal S, Nordestgaard BG, Dahl M. Low-density lipoprotein cholesterol and risk of COPD: Copenhagen General Population Study. ERJ Open Res. 2023; 9(2):00496-2022. PMID: 36891075.

29. Kahnert K, Lucke T, Huber RM, Behr J, Biertz F, Vogt A, et al. Relationship of hyperlipidemia to comorbidities and lung function in COPD: results of the COSYCONET cohort. PLoS One. 2017; 12(5):e0177501. PMID: 28505167.

30. Fang NN, Wang ZH, Li SH, Ge YY, Liu X, Sui DX. Pulmonary function in metabolic syndrome: a meta-analysis. Metab Syndr Relat Disord. 2022; 20(10):606–617. PMID: 36125502.

31. Arvanitis M, Lowenstein CJ. Dyslipidemia. Ann Intern Med. 2023; 176(6):ITC81–ITC96. PMID: 37307585.

32. Baffi CW, Wood L, Winnica D, Strollo PJ Jr, Gladwin MT, Que LG, et al. Metabolic syndrome and the lung. Chest. 2016; 149(6):1525–1534. PMID: 26836925.

33. Iribarren C, Reed DM, Chen R, Yano K, Dwyer JH. Low serum cholesterol and mortality. Which is the cause and which is the effect? Circulation. 1995; 92(9):2396–2403. PMID: 7586337.

34. Andrikoula M, McDowell IF. The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment. Diabetes Obes Metab. 2008; 10(4):271–278. PMID: 18333887.

35. Walldius G, de Faire U, Alfredsson L, Leander K, Westerholm P, Malmström H, et al. Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio-Experience from the Swedish AMORIS cohort: a cohort study. PLoS Med. 2021; 18(12):e1003853. PMID: 34851955.

36. Barochia AV, Kaler M, Cuento RA, Gordon EM, Weir NA, Sampson M, et al. Serum apolipoprotein A-I and large high-density lipoprotein particles are positively correlated with FEV₁ in atopic asthma. Am J Respir Crit Care Med. 2015; 191(9):990–1000. PMID: 25692941.

37. Visser E, de Jong K, van Zutphen T, Kerstjens HA, Ten Brinke A. Muscle function in moderate to severe asthma: association with clinical outcomes and inflammatory markers. J Allergy Clin Immunol Pract. 2023; 11(5):1439–1447.e3. PMID: 36693537.

38. Lim JE, Kim HM, Kim JH, Baek HS, Han MY. Association between dyslipidemia and asthma in children: A systematic review and multicenter cohort study using a common data model. Clin Exp Pediatr. 2023; 66(8):357–365. PMID: 37321588.

39. Sniderman AD, Faraj M. Apolipoprotein B, apolipoprotein A-I, insulin resistance and the metabolic syndrome. Curr Opin Lipidol. 2007; 18(6):633–637. PMID: 17993808.

40. Rashid S, Patterson BW, Lewis GF. Thematic review series: patient-oriented research. What have we learned about HDL metabolism from kinetics studies in humans? J Lipid Res. 2006; 47(8):1631–1642. PMID: 16685079.

41. Barzilay JI, Cotsonis GA, Walston J, Schwartz AV, Satterfield S, Miljkovic I, et al. Insulin resistance is associated with decreased quadriceps muscle strength in nondiabetic adults aged >or=70 years. Diabetes Care. 2009; 32(4):736–738. PMID: 19171728.

42. McDonough JE, Yuan R, Suzuki M, Seyednejad N, Elliott WM, Sanchez PG, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med. 2011; 365(17):1567–1575. PMID: 22029978.

43. Gyawali S, López-Cervantes JP, Johannessen A, Gislason T, Holm M, Janson C, et al. Maternal and paternal tuberculosis is associated with increased asthma and respiratory symptoms in their offspring: a study from Northern Europe. Front Allergy. 2023; 4:1193141. PMID: 37361110.

44. Weijmans M, van der Graaf Y, Reitsma JB, Visseren FL. Paternal or maternal history of cardiovascular disease and the risk of cardiovascular disease in offspring. A systematic review and meta-analysis. Int J Cardiol. 2015; 179:409–416. PMID: 25464496.

45. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005; 26(5):948–968. PMID: 16264058.